Liposomal Irinotecan Shortening Regimens : A multicenter prospective observational study

parallel administration of LV and nal-IRI during fluorouracil (5FU)/lebophorinato (LV)/liposomal irinotecan (nal-IRI) regimen for pancreatic cancer : A multicenter prospective observational study - S-NALI study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048315

Enrollment

Registered

2022-07-07

Start date

2022-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.More than 20 years old 2.Diagnosis of invasive pancreatic ductal carcinoma (including Class IV/V) by histological or cytological diagnosis 3.Pancreatic cancer that is unresectable on imaging or recurrent pancreatic cancer 4.Patient is scheduled to receive 5FU/LV/nal-IRI after the second line of chemotherapy 5.Consent for this study has been obtained.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
overall survival, adverse event	—

Countries

Japan

Contacts

Public ContactKotaro Takeshita

National cancer center hepatobiliary and pancreatic oncology

ktakeshi@ncc.go.jp03-3542-2511

Outcome results